As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face ...
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet ...
Shawn Seamans, Chief Commercial Officer, CoverMyMeds | Authors | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking ...
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and ...
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a ...
Chase Heibel is director and general manager, controlled temperature technologies, at Thermo Fisher Scientific. Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s ...
DSCSA compliance is no longer a live question for most trading partners, but two new work streams, the shift to a 12-digit ...
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the ...
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk ...
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption. In the third and final installment of Pharmaceutical Commerce’s video ...
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates. The Centers for Medicare & Medicaid Services (CMS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results